NRx Pharmaceuticals, Inc.

NASDAQ:NRXP

Biotechnology

Healthcare
$2.80 +1.43%

+$0.06 today

Market cap
$124.12M
Beta
2.19
P/E (TTM)
-5.3
EPS (TTM)
-$0.76
52W Low $1.62High $5.06

Volume 2.09M

Average 1.27M

NRXP Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

NRx Pharmaceuticals, Inc.NASDAQ: NRXP

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was $272K, compared with $0 a year earlier. Trailing-twelve-month gross profit was $851K.

Context

  • Gross profit amounted to 58.8% of revenue in FY2025.
  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $272K or moves back toward the trailing-twelve-month quarterly average of $212.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$272K-42.7% QoQ
Last fiscal yearDec 2025
$720K+14500.0% YoY
LTMMar 2026
$851K+21375.0% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+14500.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
720K USD
Year-over-year change
+14500.0%

Gross Profit vs competitors

How NRXP compares with its peers on the latest reported figures

  • NRXP's LTM Mar 2026 gross profit of $851K is the 5th highest of the 9 companies compared; the peer median is $616.66K.
  • Its year-over-year change of +21375.0% is the highest of 9, against a peer median of -46.9%.
  • Gross profit amounts to 37.1% of revenue for NRXP, versus a peer median of 96.0%.
NRXP Competitors Peer median
Gross Profit for NRXP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$145.11M +6.2%-2.6%96.0%
CUECue Biopharma, Inc.LTM Mar 2026$32.65M +308.6%+180.5%99.8%
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$18.15M +2281.5%—86.4%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$1.23M +6860.8%—87.2%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$851K +21375.0%—37.1%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$0 -100.0%——
EQEquillium, Inc.LTM Mar 2026-$79K -100.3%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$1.2M -4457.3%—360.9%
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$29.86M -126.0%+164.4%—
Peer median (excluding NRXP) $616.66K-46.9%+164.4%96.0%

Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00001.23M
Cost of Revenue2K4K5K5K505K
Gross Profit(2K)(4K)(5K)(5K)720K
Gross Margin————58.8%
Research & Development20.26M17.03M13.37M6.2M3.78M
Selling, General & Admin74.94M27.3M14.21M13.5M13.06M
Operating Expenses95.2M44.33M27.58M19.7M16.94M
Depreciation & Amortization2K4K5K5K143K
EBITDA(93.04M)(39.75M)(30.03M)(24.04M)(27.81M)
EBITDA Margin————-2270.0%
Operating Income(95.2M)(44.34M)(27.59M)(19.7M)(16.22M)
Operating Margin————-1324.4%
Interest Income18249K494K44K12K
Interest Expense18K0120K1.08M671K
Other Income / Expenses2.14M4.58M(2.56M)(5.42M)(12.4M)
Income Before Tax(93.06M)(39.75M)(30.15M)(25.13M)(28.62M)
Pre-Tax Margin————-2336.5%
Income Tax Expense00000
Net Income(93.06M)(39.75M)(30.15M)(25.13M)(28.62M)
Net Margin————-2336.5%
EPS (Basic)(7.44)(0.60)(3.98)(2.39)(1.34)
EPS (Diluted)(7.44)(0.60)(3.98)(2.39)(1.34)
Weighted Avg Shares46.92M65.77M7.58M10.52M21.4M
Weighted Avg Shares (Diluted)46.92M65.77M7.58M10.52M21.4M

NRx Pharmaceuticals, Inc.

NASDAQ:NRXP

Intrinsic Alpha fair value

Locked

Current Price

$2.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.